Drug makers end Reopro stroke trial (Reuters)


Reuters - Eli Lilly and Co. and Johnson &
Johnson's Centocor unit said on Friday they permanently halted
a joint late-stage trial of the blood-clot drug Reopro for
stroke patients after an independent safety board found a
higher-than-expected rate of brain hemorrhaging.